Brazil's Anvisa Approves New Treatment for Rare Post-Transplant Disease

Brazil's health regulator Anvisa approved a new medicine for a rare post-transplant disease, intended for patients unresponsive to other systemic therapies. The approval expands treatment options in a niche therapeutic area, but details on efficacy, pricing, and market impact remain undisclosed. This is a regulatory milestone for the manufacturer and a potential benefit for affected patients in Brazil.